6-Chloro-1-(pyridin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidine | 1352319-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 6-Chloro-1-(pyridin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidine
• 英文别名: 6-chloro-1-(pyridin-3-ylmethyl)pyrazolo[3,4-d]pyrimidine
• CAS: 1352319-13-1
• 化学式: C₁₁H₈ClN₅
• 分子量: 245.671
• InChiKey: LZEYROSDZZUCGK-UHFFFAOYSA-N

物化性质

• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氨基-1,3-二氢吲哚-2-酮 、 6-Chloro-1-(pyridin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidine 以 二甲基亚砜 为溶剂， 生成 5-((1-(pyridin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)indolin-2-one
  参考文献：
  名称：

  [EN] COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS
  [FR] COMPOSÉS PERMETTANT DE RÉGULER LES VOIES FAK ET/OU SRC

  摘要：

  本申请提供了新颖的可选择替代的融合吡啶和嘧啶双环化合物及其药用可接受盐。还提供了制备这些化合物的方法。通过向受试者投予一种或多种化合物的治疗有效量，这些化合物在共调节FAK和/或Src活性方面具有用处。通过这样做，这些化合物在治疗与FAK和/或Src途径失调相关的疾病方面具有有效性。这些化合物作为双重FAK和/或Src抑制剂表现出优势。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。

  公开号：

  WO2015038417A1

文献信息

• NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
  申请人：Woller Kevin R.

  公开号：US20120015963A1

  公开（公告）日：2012-01-19

  The present disclosure is directed to novel compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Crohn's disease, psoriasis and asthma.

  本公开涉及公式（I）的新化合物，其中所述变量如定义所述，其药学上可接受的盐、前药、生物活性代谢物、立体异构体和同分异构体。公式（I）的化合物可用作激酶抑制剂，因此可用于治疗某些情况和疾病，特别是炎症性疾病和增殖性疾病和情况，例如类风湿性关节炎、系统性红斑狼疮、多发性硬化症、克罗恩病、银屑病和哮喘。
• US8637529B2
  申请人：——

  公开号：US8637529B2

  公开（公告）日：2014-01-28
• [EN] NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE PYRAZOLO[3,4-D]PYRIMIDINE
  申请人：ABBOTT LAB

  公开号：WO2011156698A2

  公开（公告）日：2011-12-15

  The present disclosure is directed to novel compounds of Formula (I), pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Crohn's disease, psoriasis and asthma.
• [EN] COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS<br/>[FR] COMPOSÉS PERMETTANT DE RÉGULER LES VOIES FAK ET/OU SRC
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015038417A1

  公开（公告）日：2015-03-19

  The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的可选择替代的融合吡啶和嘧啶双环化合物及其药用可接受盐。还提供了制备这些化合物的方法。通过向受试者投予一种或多种化合物的治疗有效量，这些化合物在共调节FAK和/或Src活性方面具有用处。通过这样做，这些化合物在治疗与FAK和/或Src途径失调相关的疾病方面具有有效性。这些化合物作为双重FAK和/或Src抑制剂表现出优势。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。